Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02661022 · ClinicalTrials.gov registry record · Phase 1
SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma
A Phase 1 study, sponsored by Stemline Therapeutics.
- Terminated
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02661022 is a Phase 1 study that was terminated before completion, run by Stemline Therapeutics. The registered enrollment target is 9 participants.
The verdict
NCT02661022, a Phase 1 study, was terminated before completion, sponsored by Stemline Therapeutics.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
Interventions
- DRUG SL-401 7 µg/kg/day
- DRUG SL-401 9 µg/kg/day
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2016-01 |
| Est. Completion | 2019-12 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02661022
The ClinicalTrials.gov registry entry for NCT02661022 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Stemline Therapeutics, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which SL-401 7 µg/kg/day is the first listed.
NCT02661022 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02661022 about?
NCT02661022 is a clinical study titled "SL-401 in Combination With Pomalidomide and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma". A Phase 1/2, Open Label Study of SL-401 in Combination with Pomalidomide and Dexamethasone In Relapsed and Refractory Multiple Myeloma
What is the current status of trial NCT02661022?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2016-01. Estimated completion is 2019-12.
What interventions are being tested in trial NCT02661022?
The interventions under investigation include: SL-401 7 µg/kg/day (DRUG), SL-401 9 µg/kg/day (DRUG).
Who is sponsoring clinical trial NCT02661022?
This trial is sponsored by Stemline Therapeutics, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.